WVP
ITOS

Worth Venture Partners’s iTeos Therapeutics ITOS Stock Holding History

Worth Venture Partners’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,900
Closed -$144K – 178
2023
Q2 		$144K Buy
+10,900
New +$155K 0.08% 123
2023
Q1 		– Sell
-12,766
Closed -$268K – 208
2022
Q4 		$268K Buy
+12,766
New +$249K 0.16% 100

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Worth Venture Partners's ITOS Position: Q3 2023 in Review

Worth Venture Partners sold out of iTeos Therapeutics (ITOS) in Q3 2023, closing a stake of 10,900 shares — an estimated $144K sold.

Worth Venture Partners first reported a position in ITOS in Q4 2022 and held it in 2 quarters. The position peaked at $268K in Q4 2022. 144 funds tracked by Wall St. Rank hold ITOS as of Q3 2023.

  • Worth Venture Partners reported no remaining iTeos Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Worth Venture Partners sold 10,900 iTeos Therapeutics shares in Q3 2023, an estimated $144K.
  • Worth Venture Partners first reported a position in iTeos Therapeutics in Q4 2022 and held it in 2 quarters.
  • Worth Venture Partners's iTeos Therapeutics position peaked at $268K in Q4 2022.
  • 144 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2023.

Based on Worth Venture Partners's 13F filing for Q3 2023, filed 15 Nov 2023.